SAN DIEGO, March 24, 2020 — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer (CMO), and Anja Kammesheidt, Ph.D., as Chief Scientific Officer (CSO). The addition of Drs. Zack and Kammesheidt to the Exagen team will …

SAN DIEGO, March 11, 2020 — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it will release financial results for the fourth quarter and year-end 2019 after the market closes on Wednesday, March 25, 2020. …

Monday, March 9, 2020 SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the careontinuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced three large medical groups across California have contracted with Exagen Inc. to offer AVISE testing as a covered benefit for patients …

December 16, 2019 SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it will be added to the Russell 3000® and 2000® Indexes, effective after the US market opens on December 23, …

SAN DIEGO, CA, December 10, 2019 (GLOBE NEWSWIRE) – Exagen Inc. (Nasdaq:XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has formed a Scientific Advisory Board (SAB) consisting of national experts in the clinical management of rheumatic autoimmune …

SAN DIEGO, CA, Nov. 22, 2019 (GLOBE NEWSWIRE) – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has extended its collaboration agreement with GlaxoSmithKline plc (GSK), one of the world’s leading healthcare companies, to …

November 21, 2019 SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an affiliate of Innovatus Capital …